当前位置: 首页 >> 检索结果
共有 7024 条符合本次的查询结果, 用时 1.8926796 秒

6941. SNPs in the FOXP3 gene region show no association with Juvenile Idiopathic Arthritis in a UK Caucasian population.

作者: T Eastell.; .;A Hinks.;W Thomson.
来源: Rheumatology (Oxford). 2007年46卷8期1263-5页
A region on the short arm of the X-chromosome, Xp11, has previously been linked to childhood-onset polyarthritis. Mapping to the linked region is FOXP3, a transcription factor that regulates regulatory T cell (T(reg)) development and function. The objective of this study was to determine whether single nucleotide polymorphisms (SNPs) in the FOXP3 gene region contribute to JIA susceptibility.

6942. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout.

作者: Kelsey M Jordan.;J Stewart Cameron.;Michael Snaith.;Weiya Zhang.;Michael Doherty.;Jonathan Seckl.;Aroon Hingorani.;Richard Jaques.;George Nuki.; .
来源: Rheumatology (Oxford). 2007年46卷8期1372-4页

6943. Do baseline characteristics predict response to treatment for low back pain? Secondary analysis of the UK BEAM dataset [ISRCTN32683578].

作者: M R Underwood.;V Morton.;A Farrin.; .
来源: Rheumatology (Oxford). 2007年46卷8期1297-302页
To identify characteristics of randomized controlled trial participants which predict greater benefits from physical treatments for low back pain. If successful, this would allow more appropriate selection of patients for different treatments.

6944. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.

作者: S Bombardieri.;A A Ruiz.;P Fardellone.;P Geusens.;F McKenna.;K Unnebrink.;U Oezer.;S Kary.;H Kupper.;G R Burmester.; .
来源: Rheumatology (Oxford). 2007年46卷7期1191-9页
To evaluate the effectiveness and safety of adalimumab in patients with rheumatoid arthritis (RA) who previously discontinued tumour necrosis factor (TNF) antagonists for any reason in clinical practice.

6945. Provisional guidelines for applying the Department of Health (England) 18-week-patient pathway to specialist rheumatology care.

作者: D A Walsh.;C Kelly.;A Bosworth.;C Price.;G Burbage.
来源: Rheumatology (Oxford). 2007年46卷7期1200-6页
The Government Department of Health (England) has set a target that by 2008 patients on pathways that do or may involve medical or surgical consultant-led care should wait no longer than 18 weeks from referral to start of definitive treatment. Department of Health guidance must be interpreted and applied to patients with rheumatological problems.

6946. Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis.

作者: C A E Walsh.;P Minnock.;C Slattery.;N Kennedy.;F Pang.;D J Veale.;B Bresnihan.;O FitzGerald.
来源: Rheumatology (Oxford). 2007年46卷7期1148-52页
To evaluate the quality of life and economic impact of switching therapy from infliximab to adalimumab in patients with rheumatoid arthritis (RA).

6947. Combining enzyme specificity and tissue selectivity of cyclooxygenase inhibitors: towards better tolerability?

作者: K Brune.;D E Furst.
来源: Rheumatology (Oxford). 2007年46卷6期911-9页
Inhibitors of cyclooxygenases (COXs) are the most widely used drugs. They reduce discomfort and fever, inhibit peri-operative and inflammatory pain. These effects are largely mediated by inhibition of cyclooxygenase-1 and -2 (COX-1 and COX-2)-enzymes found throughout the body producing prostaglandins, which are important mediators of pain and fever, but also adaptive and protective reactions in many organs. A first step to reduce the overall toxicity and to increase the anti-inflammatory activity of these drugs was achieved with the development of acidic 'non-selective' (traditional) non-steroidal anti-inflammatory drugs (tNSAIDs). These agents distribute unequally throughout the body, reaching effective concentrations in inflamed tissue (effect compartment) for prolonged time periods. They can also reach effective concentrations in the bloodstream, kidney and gastrointestinal (GI) mucosa, where they can cause unwanted effects, such as GI toxicity, kidney dysfunction and cardiovascular impairment. All these effects are particularly prominent with compounds which are eliminated slowly [half-life (T((1/2))) >12 h] and thus also block prostaglandin production permanently outside the effect compartment. A second step towards improving safety was achieved with selective COX-2 inhibitors. These agents reduce the incidence of GI toxicity, pseudo-asthmatic reactions and blood loss following surgical interventions. However, they may be more toxic to the cardiovascular and renal systems than some tNSAIDs, possibly because they distribute homogeneously throughout the body and inhibit COX-2 in the endothelial layer of the vessels and the kidney permanently due to their slow elimination. Another step towards improvement in safety appears possible by combining both enzyme specificity and tissue selectivity, to achieve a further reduction of unwanted drug effects while maintaining the anti-inflammatory/analgesic efficacy.

6948. The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis.

作者: E C F Wilson.;D R W Jayne.;E Dellow.;R J Fordham.
来源: Rheumatology (Oxford). 2007年46卷7期1096-101页
Systemic lupus erythematosus (SLE) is an autoimmune disorder that can affect any system of the body. Involvement of the kidneys, lupus nephritis (LN), affects up to 50% of SLE patients during the course of their disease, and is characterized by periods of active disease (flares) and remission. For more severe nephritis, an induction course of immunosuppressive therapy is recommended. Options include intravenous cyclophosphamide (IVC) or mycophenolate mofetil (MMF), followed by a maintenance course, typically of azathioprine. The objective of this study is to determine which therapy results in better quality of life (QoL) for patients and which represents best value for money for finite health service resources.

6949. Acculturation and the prevalence of pain amongst South Asian minority ethnic groups in the UK.

作者: B Palmer.;G Macfarlane.;C Afzal.;A Esmail.;A Silman.;M Lunt.
来源: Rheumatology (Oxford). 2007年46卷6期1009-14页
Musculoskeletal pain is reported more commonly by South Asians in the UK than by white Europeans. This may result from a variety of factors, including cultural differences, and thus we investigated the extent to which differences in the prevalence of pain within the South Asian population could be explained by differences in acculturation (the extent to which immigrants take on the culture of their host population).

6950. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.

作者: J Braun.;N McHugh.;A Singh.;J S Wajdula.;R Sato.
来源: Rheumatology (Oxford). 2007年46卷6期999-1004页
The objective of this study was to assess the humanistic impact of ankylosing spondylitis (AS), and compare the effect of etanercept 50 mg once-weekly (QW), etanercept 25 mg twice-weekly (BIW) and placebo on patient-reported outcomes (PROs).

6951. Development of active tuberculosis following initiation of infliximab despite appropriate prophylaxis.

作者: S Raychaudhuri.;R Shmerling.;J Ermann.;S Helfgott.
来源: Rheumatology (Oxford). 2007年46卷5期887-8页

6952. Skin involvement in scleroderma--where histological and clinical scores meet.

作者: F Verrecchia.;J Laboureau.;O Verola.;N Roos.;R Porcher.;P Bruneval.;M Ertault.;K Tiev.;L Michel.;A Mauviel.;D Farge.
来源: Rheumatology (Oxford). 2007年46卷5期833-41页
A clinico-pathological study in diffuse systemic sclerosis (SSc) patients was performed to analyse whether the skin histological organization and the pro-fibrotic signals elicited by TGF-beta in fibroblasts vary according to the modified Rodnan skin score (mRSS).

6953. Development of a competency framework for general practitioners with a special interest in musculoskeletal/rheumatology practice.

作者: E M Hay.;A Campbell.;S Linney.;E Wise.; .
来源: Rheumatology (Oxford). 2007年46卷2期360-2页

6954. Unilateral polymyalgia rheumatica with controlateral sympathetic dystrophy syndrome. A case of asymmetrical involvement due to pre-existing peripheral palsy.

作者: G Bordin.;F Atzeni.;L Bettazzi.;N B Beyene.;M Carrabba.;P Sarzi-Puttini.
来源: Rheumatology (Oxford). 2006年45卷12期1578-80页

6955. Autologous haematopoeitic stem cell rescue (AHSCR) for severe rheumatic disease in children: guidance for BSPAR members--executive summary.

作者: H Foster.;J Davidson.;E Baildam.;M Abinun.;L R Wedderburn.; .
来源: Rheumatology (Oxford). 2006年45卷12期1570-1页

6956. Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years.

作者: V Strand.;A Balbir-Gurman.;K Pavelka.;P Emery.;N Li.;M Yin.;P B Lehane.;S Agarwal.
来源: Rheumatology (Oxford). 2006年45卷12期1505-13页
To evaluate the long-term impact on physical function of a single course of rituximab in rheumatoid factor, seropositive patients with active rheumatoid arthritis (RA) despite ongoing methotrexate treatment.

6957. Urinary proteomic profiles distinguish between active and inactive lupus nephritis.

作者: K Mosley.;F W K Tam.;R J Edwards.;J Crozier.;C D Pusey.;L Lightstone.
来源: Rheumatology (Oxford). 2006年45卷12期1497-504页
Key aims of the treatment of lupus nephritis (LN) are to induce and maintain remission with minimal side effects. However, assessing ongoing renal inflammatory activity is poorly served by current diagnostic tests apart from renal biopsy, but frequent biopsies cannot be justified. Our long-term aim is to identify novel biomarkers from urinary protein profiles to improve diagnosis and monitoring of activity and response to therapy in LN.

6958. BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists.

作者: K Chakravarty.;H McDonald.;T Pullar.;A Taggart.;R Chalmers.;S Oliver.;J Mooney.;M Somerville.;A Bosworth.;T Kennedy.; .; .
来源: Rheumatology (Oxford). 2008年47卷6期924-5页

6959. Time use patterns among women with rheumatoid arthritis: association with functional limitations and psychological status.

作者: P Katz.;A Morris.
来源: Rheumatology (Oxford). 2007年46卷3期490-5页
This study assessed time use patterns among 375 women with rheumatoid arthritis (RA). We hypothesized that (i) as functional limitations increased, time use imbalances would occur (i.e. time needed for obligatory activities would conflict with time needed for productive and free-time activities) and (ii) time use imbalances would be associated with psychological distress.

6960. Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system.

作者: P Szodoray.;P Alex.;C M Chappell-Woodward.;T M Madland.;N Knowlton.;I Dozmorov.;M Zeher.;J N Jarvis.;B Nakken.;J G Brun.;M Centola.
来源: Rheumatology (Oxford). 2007年46卷3期417-25页
Serum cytokines play an important role in the pathogenesis of psoriatic arthritis (PsA) by initiating and perpetuating various cellular and humoral autoimmune processes. The aim of this study was to describe a broad spectrum of T- and B-cell cytokines, growth factors and chemokines in patients with PsA and healthy individuals.
共有 7024 条符合本次的查询结果, 用时 1.8926796 秒